BerningSEMadsenLIsemanMDPeloquinCA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med1995;151:2006–9.
2.
PeloquinCABerningSEMadsenLIsemanMD. Ofloxacin and ciprofloxacin in the treatment of mycobacterial infections: Development of resistance and drug interactions. J Infect Dis Pharmacother1995;1:45–65.
3.
KaplanJAKrieffDM. Quinolones for the treatment and prophylaxis of tuberculosis. Ann Pharmacother1996;30:1020–2.
4.
PeloquinCA. Quinolones and tuberculosis (editorial). Ann Pharmacother1996;30:1034–5.
5.
KennedyNBergerLCurramJFoxRGutmannJKisyombeGMRandomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis1996;22:827–33.
6.
MorNVanderkolkJHeifetsL. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother1994;38:1161–4.
7.
DrlicaKXuCWangJYBurgerRMMalikM. Fluoroquinolone action in mycobacteria: Similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob Agents Chemother1996;40:1594–9.
8.
KocagözTHackbarthCJÜnsalIRosenbergEYNikaidoHChambersHF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother1996;40:1768–74.
9.
EbertSCCraigWA. Pharmacodymanic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol1990;11:319–26.
10.
PeloquinCA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med1997;18:79–87.
11.
DavisRBrysonHM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics, and therapeutic efficacy. Drugs1994;47:677–700.
